There is no evidence that semaglutide reduces antibiotic efficacy for any common indication
Why Plan Sponsors and Brokers Should Care About GLP-1s GLP-1s have been approved to treat diabetes and weight loss, and are showing promise in the treatment of other cardiometabolic diseases
- Find Care for Your Concern Select your health concern to explore personalized solutions
Glitza Oliva IC, Ferguson SD, Bassett R, Foster AP, John I, Hennegan TD, Rohlfs M, Richard J, Iqbal M, Dett T, Lacey C, Jackson N, Rodgers T, Phillips S, Duncan S, Haydu L, Lin R, Amaria RN, Wong MK, Diab A, Yee C, Patel SP, McQuade JL, Fischer GM, McCutcheon IE, O'Brien BJ, Tummala S, Debnam M, Guha-Thakurta N, Wargo JA, Burton EM, Tawbi HA, Davies MA
7 Clinical case reports have documented patients who fasted appropriatelybetween 7 and 18 hoursyet still presented with residual gastric contents before elective procedures
Clinical trials have indicated a weight reduction averaging around 15% over 68 weeks with Wegovy